---
figid: PMC5721746__JAH3-6-e006441-g006
figlink: /pmc/articles/PMC5721746/figure/jah32744-fig-0006/
number: Figure 6
caption: Proposed mechanism(s) underlying the improvement of endothelium‐dependent
  vasodilation after Roux‐en‐Y gastric bypass (RYGB). Higher circulating glucagon‐like
  peptide‐1 (GLP‐1) after RYGB activates the endothelial GLP‐1 receptor and downstream
  protein kinase A (PKA), which inhibits c‐Jun N‐terminal kinase (JNK) 2. JNK2 directly
  inhibits endothelial NO synthase (eNOS) and insulin receptor substrate‐1 (IRS‐1)
  in the insulin signaling pathway; PKA and IRS‐1 lead to protein kinase B (Akt) activation,
  which then directly stimulates eNOS. This, in turn, leads to improved NO bioavailability
  and vasodilation. In parallel, JNK2 inactivation inhibits reduced nicotinamide ADP
  (NADPH) oxidase activity and decreases the levels of superoxide anions, which further
  contributes to preserved NO bioavailability and vasodilation. These beneficial effects
  of RYGB were mimicked by in vivo pharmacological JNK inhibition. Blue and red arrows
  indicate experimentally observed activation and inactivation, respectively, of proposed
  downstream mediators. D‐JNK indicates peptide inhibitor D‐JNKi‐1; and p, phosphorylated.
pmcid: PMC5721746
papertitle: Inhibition of Vascular c‐Jun N‐Terminal Kinase 2 Improves Obesity‐Induced
  Endothelial Dysfunction After Roux‐en‐Y Gastric Bypass.
reftext: Petia Doytcheva, et al. J Am Heart Assoc. 2017 Nov;6(11):e006441.
pmc_ranked_result_index: '164648'
pathway_score: 0.9591256
filename: JAH3-6-e006441-g006.jpg
figtitle: Proposed mechanism(s) underlying the improvement of endothelium‐dependent
  vasodilation after Roux‐en‐Y gastric bypass (RYGB)
year: '2017'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5721746__JAH3-6-e006441-g006.html
  '@type': Dataset
  description: Proposed mechanism(s) underlying the improvement of endothelium‐dependent
    vasodilation after Roux‐en‐Y gastric bypass (RYGB). Higher circulating glucagon‐like
    peptide‐1 (GLP‐1) after RYGB activates the endothelial GLP‐1 receptor and downstream
    protein kinase A (PKA), which inhibits c‐Jun N‐terminal kinase (JNK) 2. JNK2 directly
    inhibits endothelial NO synthase (eNOS) and insulin receptor substrate‐1 (IRS‐1)
    in the insulin signaling pathway; PKA and IRS‐1 lead to protein kinase B (Akt)
    activation, which then directly stimulates eNOS. This, in turn, leads to improved
    NO bioavailability and vasodilation. In parallel, JNK2 inactivation inhibits reduced
    nicotinamide ADP (NADPH) oxidase activity and decreases the levels of superoxide
    anions, which further contributes to preserved NO bioavailability and vasodilation.
    These beneficial effects of RYGB were mimicked by in vivo pharmacological JNK
    inhibition. Blue and red arrows indicate experimentally observed activation and
    inactivation, respectively, of proposed downstream mediators. D‐JNK indicates
    peptide inhibitor D‐JNKi‐1; and p, phosphorylated.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NCF4
  - CYBA
  - PRKACB
  - PRKACG
  - CYBB
  - PRKAR1A
  - IRS1
  - NOX5
  - NOS3
  - RAC1
  - NCF1
  - NCF2
  - PRKAR1B
  - DUOX1
  - NOX1
  - PRKAR2B
  - PRKACA
  - DUOX2
  - NOX3
  - NOX4
  - AKT1
  - PRKAR2A
  - AKT3
  - AKT2
genes:
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: NCF4
  entrez: '4689'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: CYBA
  entrez: '1535'
- word: p-PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: p-PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: CYBB
  entrez: '1536'
- word: p-PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: p-IRS-1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: NOX5
  entrez: '79400'
- word: ENOS
  symbol: eNOS
  source: hgnc_alias_symbol
  hgnc_symbol: NOS3
  entrez: '4846'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: RAC1
  entrez: '5879'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: NCF1
  entrez: '653361'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: NCF2
  entrez: '4688'
- word: p-PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: DUOX1
  entrez: '53905'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: NOX1
  entrez: '27035'
- word: p-PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: p-PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: DUOX2
  entrez: '50506'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: NOX3
  entrez: '50508'
- word: NADPHoxidase
  symbol: NADPH_oxidase
  source: bioentities_symbol
  hgnc_symbol: NOX4
  entrez: '50507'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: p-PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
chemicals: []
diseases: []
---
